Related Experiment Video
Updated: Jan 17, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.6K
Selatogrel: Potential to redefine timely anti-platelet intervention
Rudy N Zalzal1, Peter P Salem1, Ali H Dakroub2
1Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
British Journal of Pharmacology
|September 20, 2025
Summary
Selatogrel, a new P2Y12 antagonist, offers rapid, subcutaneous intervention for acute coronary syndrome (ACS). Its favorable profile suggests potential for pre-hospital self-administration, reducing ischemic time.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndrome (ACS) is a significant cardiovascular disease burden.
- Current dual antiplatelet therapy (DAPT) for ACS has pharmacokinetic and pharmacodynamic limitations.
Purpose of the Study:
- To evaluate selatogrel, a novel P2Y12 antagonist, for acute coronary syndrome (ACS) management.
- To assess selatogrel's potential for rapid, pre-hospital, self-administered treatment.
Main Methods:
- Selatogrel is a novel, selective P2Y12 receptor antagonist.
- Administered subcutaneously, it offers immediate intervention.
- Phase I and II trials completed; Phase III trials are ongoing.
Main Results:
- Selatogrel demonstrates a rapid onset of action.
- It possesses a favorable safety profile.
- Potential to reduce total ischemic time in ACS patients.
Conclusions:
- Selatogrel is a promising candidate for revolutionizing ACS treatment.
- Its characteristics support potential use in pre-hospital settings.
- Further Phase III investigations will refine its therapeutic attributes.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:27Peripheral Artery Disease III: Interprofessional Care
248
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
01:26Angina IV: Management
238
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
238
01:29Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280